TransMedics Group/$TMDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Ticker
$TMDX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
728
ISIN
US89377M1099
Website
TMDX Metrics
BasicAdvanced
$4.4B
92.32
$1.41
1.90
-
Price and volume
Market cap
$4.4B
Beta
1.9
52-week high
$177.37
52-week low
$55.00
Average daily volume
848K
Financial strength
Current ratio
9.099
Quick ratio
8.132
Long term debt to equity
193.618
Total debt to equity
194.666
Interest coverage (TTM)
3.68%
Profitability
EBITDA (TTM)
74.111
Gross margin (TTM)
59.47%
Net profit margin (TTM)
10.03%
Operating margin (TTM)
10.76%
Effective tax rate (TTM)
2.23%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
4.20%
Return on equity (TTM)
22.99%
Valuation
Price to earnings (TTM)
92.318
Price to revenue (TTM)
8.916
Price to book
16.52
Price to tangible book (TTM)
17.41
Price to free cash flow (TTM)
-68.85
Free cash flow yield (TTM)
-1.45%
Free cash flow per share (TTM)
-188.90%
Growth
Revenue change (TTM)
64.43%
Earnings per share change (TTM)
-545.62%
3-year revenue growth (CAGR)
132.02%
3-year earnings per share growth (CAGR)
-5.89%
What the Analysts think about TMDX
Analyst ratings (Buy, Hold, Sell) for TransMedics Group stock.
Bulls say / Bears say
TransMedics Group reported a 167% year-over-year revenue increase in Q1 2025, indicating strong demand for its organ transplant technology (seekingalpha.com).
The company received FDA approval for its OCS Heart system in March 2025, expanding its market reach and potential revenue streams (reuters.com).
TransMedics announced a strategic partnership with a leading hospital network in April 2025, which is expected to drive adoption of its organ care systems (bloomberg.com).
Despite revenue growth, TransMedics reported a net loss of $10 million in Q1 2025, raising concerns about profitability (seekingalpha.com).
The company's reliance on a limited number of suppliers for critical components poses a risk to its supply chain stability (reuters.com).
TransMedics faces increasing competition from emerging biotech firms developing alternative organ preservation technologies (bloomberg.com).
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TMDX Financial Performance
Revenues and expenses
TMDX Earnings Performance
Company profitability
TMDX News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out
Accesswire·2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation
Accesswire·2 weeks ago
Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May
MarketBeat·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TransMedics Group stock?
TransMedics Group (TMDX) has a market cap of $4.4B as of June 27, 2025.
What is the P/E ratio for TransMedics Group stock?
The price to earnings (P/E) ratio for TransMedics Group (TMDX) stock is 92.32 as of June 27, 2025.
Does TransMedics Group stock pay dividends?
No, TransMedics Group (TMDX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next TransMedics Group dividend payment date?
TransMedics Group (TMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for TransMedics Group?
TransMedics Group (TMDX) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.